Online inquiry

IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12305MR)

This product GTTS-WQ12305MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CSF2 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000758.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1437
UniProt ID P04141
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12305MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8478MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HTI-1088
GTTS-WQ15806MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA XmAb14045
GTTS-WQ1462MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ11116MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MDX-060
GTTS-WQ15479MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA UCB-0107
GTTS-WQ13514MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PRX002
GTTS-WQ1423MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACA125
GTTS-WQ7607MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA G-CSF-Fc-PEG
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW